https://www.selleckchem.com/pr....oducts/pf-07104091.h
es. In addition, the panel decided that contextual factors such as resources, feasibility, acceptability, and equity for countries and health care systems did not alter the recommendation. This is a living guideline. It replaces earlier versions (4 September and 20 November 202 and supersedes the BMJ Rapid Recommendations on remdesivir published on 2 July 2020. The previous versions can be found as data supplements. New recommendations will be published as updates to this guideline. This is the third version (update 2) of the livi